Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

July 16, 2026
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

July 13, 2026July 13, 2026

Why Do We Age? The Biology Of Ageing Explained

1
October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

2
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

3
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

4
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

5
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

6

Search Field

Subscribe Now

  • Home
  • BiotechToday
  • Oncogenic mutations in K-Ras CaM interactions

MegaLMM: A software program for genomic predictions

ATF4: A stress-responsive factor in mTORC1 signaling

Oncogenic mutations in K-Ras CaM interactions
  • BiotechToday
  • World

Oncogenic mutations in K-Ras CaM interactions

BioTech Today July 27, 2021July 26, 2021

Husna, Amity University Kolkata

What is K-Ras-CaM interaction?

K-Ras is an oncogenic mutant that helps the cancer cells to proliferate, migrate, invade, and survive by assembling some signalling complexes. These complexes have a great therapeutic and mechanistic significance, however, to date, the functional and structural roles of K-Ras mutations within these complexes are not completely understood. K-Ras GTPase specifically binds to a calcium sensor known as calmodulin (CaM). This binding helps to regulate signal transduction in cancer and it remains the primary focus of intense research. 

Recent study: A 2021 study has reviewed recent advances to understand specific binding between K-Ras and calmodulin (calcium sensor). The review published in Current Opinion in Structural Biology has highlighted the key features of the interaction between wild-type K-Ras and calmodulin (CaM).

Insights into K-Ras-CaM interaction:

For the development of a proper signalling cascade, tight spatial and temporal regulation of proteins is highly essential. A ubiquitous regulator of many essential cellular signalling processes in health and disease is calmodulin (CaM). Calmodulin (CaM) is a small protein that is 148 amino acids long and it comprises two globular domains that are connected by a flexible linker. Each of the domains can bind two calcium ions. However, the calcium affinity of the N-terminal domain is lower in comparison to the C-terminal domain; this difference in affinity allows CaM’s conformations to adapt in response to changing calcium concentrations. Protein-protein complexes involving CaM are highly sensitive to environmental conditions and it depends on pH and concentrations of metal ions. 

So, the binding of CaM to other proteins can modulate signalling cascades. GTPases are one of these groups of proteins, they are a family of signal transduction proteins. CaM is able to bind to several members of this family, followed by controlling their signalling cascades in a disease-specific manner. Ras family of GTPases, particularly Kirsten Ras isoform B (K-Ras4B), are vital oncogenic proteins that drive the cancer of epithelial origin, such as pancreatic, lung, and colorectal malignancies. 

K-Ras lacks the ability to be palmitoylated; it is polybasic and its hypervariable region on C-terminal is carboxymethylated and farnesylated. So, these are the distinct features of K-Ras’s HVR, responsible for selective binding to CaM As the functions of K-Ras in cancer cells can directly be regulated by CaM so this interaction is a focus of intense research. 

Oncogenic mutations of K-Ras alter the nature of interaction with CaM:

Oncogenic mutations in K-Ras occur at position 12 which inhibits the hydrolysis of GTP and traps the enzyme in a constitutively active state. Due to oncogenic mutations, there is a differential preference of membrane components and distinct signalling pathways which can further modulate CaM’s ability to extract oncogenic K-Ras from the membrane. By using isothermal titration calorimetry, it was shown that farnesylation is unlikely to be the only essential requirement in the formation of the K-Ras/CaM complex and instead it might strengthen this interaction further and help to attain a physiologically relevant affinity of oncogenic K-Ras for CaM.

Significance of the study:

• Studies of calmodulin complexes (CaM) with oncogenic mutants of K-Ras can give insights into the invention of some novel regulatory mechanisms, especially in cancer.

• Insights into K-Ras/CaM interactions may help to design some selective drugs.

Also read: Reverse optogenetics tool using zebrafish

Reference:

  1. Abdelkarim, H., Leschinsky, N., Jang, H., Banerjee, A., Nussinov, R., & Gaponenko, V. (2021). The dynamic nature of the K-Ras/calmodulin complex can be altered by oncogenic mutations. Current Opinion in Structural Biology, 71, 164–170. https://doi.org/10.1016/j.sbi.2021.06.008
  • Why Do We Age? The Biology Of Ageing Explained
  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

Author info:

Husna is an undergraduate student of BTech Biotechnology at Amity University Kolkata. She is a research enthusiast in Immunology and Immunotherapy but she has a keen interest in various other Bioscience subjects as well. She is constantly focused on improving her knowledge and laboratory skills through various internships. She is a Scientific content writer who has knowledge in diverse backgrounds of Biotechnology.

Publications:

  • https://bioxone.in/news/worldnews/is-the-frequent-prescription-of-ppi-medicines-a-boon-or-a-bane/
  • https://bioxone.in/news/worldnews/role-of-lysosomes-and-%CE%B1-synuclein-fibrils-in-protein-misfolding/

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related

Tagged calcium affinity Calmodulin complexes CaM cancer cANCER bIOLOGY farnesylation K-Ras-CaM interactions Oncogenes oncogenic mutants oncogenic mutations signalling cascades Signalling Pathways

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • BiotechToday
  • World

ATF4: A stress-responsive factor in mTORC1 signaling

BioTech Today July 27, 2021

Vaishnavi Kardale, Bioinformatics Centre, Savitribai Phule Pune University For a very long time, researchers have been searching for ways to increase human life. In this quest, they have found one promising protein -mTOR. The finding of mTOR has given rise to a whole field in cellular biology that studies mTOR and its associated pathway.  mTOR- […]

ATF4

Related Post

  • BiotechToday
  • FEATURED
  • India
  • Latest

COVID-19, not just a pulmonary but also a cardiovascular disease!

bioxone September 11, 2020September 11, 2020

–Camelia Bhattacharyya, Amity University Kolkata Our body is a natural and the most complicated machine and all of its parts are interrelated. Thus, any change in the environment of one part of the body is likely to cause other changes in most other parts. This theory also holds true when taking into account, the recent […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • India
  • World

AstraZeneca: Late-stage trial of Covid-19 antibody medicine to start soon

bioxone October 12, 2020October 12, 2020

Prama Ghosh, Amity University Kolkata After the recovery of President Donald Trump from Covid-19 using a similar therapy as of the antibody medicine from AstraZeneca Plc, the company has started its late-stage trials for the same against COVID-19. The medicine will undergo two trials on more than 60000 people starting soon. Astra has also planned […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Linked read sequencing reveals the ecological resilience of a human gut microbial community during antibiotic treatment

bioxone December 14, 2020December 14, 2020

Souradip Mallick, National Institute of Technology, Rourkela The gastrointestinal metagenome is aggregation of all the genomes of gut microbiota. The gut flora is established after birth, by which time the intestinal epithelium and the intestinal mucosal barrier that it secretes developed its tolerance and also provides a barrier to pathogenic organisms. The relationship between gut flora and humans is not merely commensal but rather a mutualistic  relationship. […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Breaking News

Why Do We Age? The Biology Of Ageing Explained

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy